Citations (111)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (41)
Chrysoula Boutari, Asterios Karagiannis & Vasilios G. Athyros. (2021) Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. Expert Review of Cardiovascular Therapy 19:7, pages 575-580.
Read now
Read now
Ya-Bin Ma, Paul Chan, Yuzhen Zhang, Brian Tomlinson & Zhongmin Liu. (2019) Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy 20:8, pages 917-928.
Read now
Read now
Marilisa Bove, Federica Fogacci & Arrigo F. G. Cicero. (2017) Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Drug Metabolism & Toxicology 13:10, pages 1099-1104.
Read now
Read now
Glenn M. Davies, Ami Vyas & Carl A. Baxter. (2017) Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. Journal of Medical Economics 20:7, pages 723-731.
Read now
Read now
T. D. Filippatos, M. Florentin, M. Georgoula & M. S. Elisaf. (2017) Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 10:2, pages 187-200.
Read now
Read now
Anastazia A. Kei, Theodosios D. Filippatos & Moses S. Elisaf. (2016) The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opinion on Drug Safety 15:4, pages 559-569.
Read now
Read now
Aris P Agouridis, Michael S Kostapanos & Moses S Elisaf. (2015) Statins and their increased risk of inducing diabetes. Expert Opinion on Drug Safety 14:12, pages 1835-1844.
Read now
Read now
Aris P Agouridis, Devaki R Nair & Dimitri P Mikhailidis. (2015) Strategies to overcome statin intolerance. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 851-855.
Read now
Read now
Aris P. Agouridis & Dimitri P. Mikhailidis. (2015) Should we consider ezetimibe to reach even lower LDL-C targets?. Current Medical Research and Opinion 31:3, pages 459-460.
Read now
Read now
Fotios Barkas, Haralampos Milionis, Michael S. Kostapanos, Dimitri P. Mikhailidis, Moses Elisaf & Evangelos Liberopoulos. (2015) How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Current Medical Research and Opinion 31:2, pages 221-228.
Read now
Read now
Elizabeth Marrett, Changgeng Zhao, Ning Jackie Zhang, Qiaoyi Zhang, Dena R Ramey, Joanne E Tomassini, Andrew M Tershakovec & David R Neff. (2014) Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. Vascular Health and Risk Management 10, pages 237-246.
Read now
Read now
Vasilios G. Athyros, Niki Katsiki & Manfredi Rizzo. (2014) Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!. Current Medical Research and Opinion 30:12, pages 2425-2428.
Read now
Read now
JoAnne M Foody, Peter P Toth, Joanne E Tomassini, Shiva Sajjan, Dena R Ramey, David Neff, Andrew M Tershakovec, Henry Hu & Kaan Tunceli. (2013) Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vascular Health and Risk Management 9, pages 719-727.
Read now
Read now
Michael Kostapanos, Moses Elisaf & Dimitri Mikhailidis. (2012) Hypertriglyceridemia-induced acute pancreatitis: clinical considerations. Clinical Lipidology 7:3, pages 259-262.
Read now
Read now
Michael S. Kostapanos, Vasilios G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2012) Therapeutic options for statin-intolerant patients. Current Medical Research and Opinion 28:3, pages 345-349.
Read now
Read now
Dimitri P. Mikhailidis, Richard W. Lawson, Anna-Louise McCormick, Gillian C. Sibbring, Andrew M. Tershakovec, Glenn M. Davies & Kaan Tunceli. (2011) The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients. Current Medical Research and Opinion 27:10, pages 1961-1961.
Read now
Read now
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Tarek AN Ahmed, Ioannis Karalis & J Wouter Jukema. (2011) Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs 16:2, pages 203-233.
Read now
Read now
Dimitri P. Mikhailidis, Richard W. Lawson, Anna-Louise McCormick, Gillian C. Sibbring, Andrew M. Tershakovec, Glenn M. Davies & Kaan Tunceli. (2011) Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Current Medical Research and Opinion 27:6, pages 1191-1210.
Read now
Read now
Niki Katsiki, Vasilis G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2011) Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Current Medical Research and Opinion 27:3, pages 693-695.
Read now
Read now
Matilda Florentin, Evangelos N. Liberopoulos, Elisavet Moutzouri, Christos V. Rizos, Alexandros D. Tselepis & Moses S. Elisaf. (2011) The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Current Medical Research and Opinion 27:3, pages 685-692.
Read now
Read now
Dick C Chan & Gerald F Watts. (2011) Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opinion on Pharmacotherapy 12:1, pages 13-30.
Read now
Read now
Maria Sarigianni, Niki Katsiki & Dimitri P Mikhailidis. (2010) Ezetimibe in diabetes: more than cholesterol lowering?. Current Medical Research and Opinion 26:10, pages 2517-2520.
Read now
Read now
Chris J Packard. (2010) Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology 3:5, pages 649-661.
Read now
Read now
Erkki J.O. Soini, Glenn Davies, Janne A. Martikainen, Henry X. Hu, Kaan Tunceli & Leo Niskanen. (2010) Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Current Medical Research and Opinion 26:1, pages 25-36.
Read now
Read now
I. Migdalis, A. Efthimiadis, St. Pappas, D. Alexopoulos, F. Vlasserou & D. P. Mikhailidis. (2009) Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Current Medical Research and Opinion 25:10, pages 2571-2576.
Read now
Read now
Jennifer M Scholle, William L Baker, Ripple Talati & Craig I Coleman. (2009) The Effect of Adding Plant Sterols or Stanols to Statin Therapy in Hypercholesterolemic Patients: Systematic Review and Meta-Analysis. Journal of the American College of Nutrition 28:5, pages 517-524.
Read now
Read now
ES Nakou, TD Filippatos, DN Kiortsis, CS Derdemezis, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opinion on Pharmacotherapy 9:18, pages 3151-3158.
Read now
Read now
John Strony, Bo Yang, Mary E. Hanson & Enrico P. Veltri. (2008) Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. Current Medical Research and Opinion 24:11, pages 3149-3157.
Read now
Read now
Steven K. Hildemann, Christian Barho, Barbara Karmann, Harald Darius & Christoph Bode. (2008) Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. Current Medical Research and Opinion 24:10, pages 2777-2784.
Read now
Read now
Jonathan Belsey, Simon de Lusignan, Tom Chan, Jeremy van Vlymen & Nigel Hague. (2008) Abnormal lipids in high-risk patients achieving cholesterol targets: a cross-sectional study of routinely collected UK general practice data. Current Medical Research and Opinion 24:9, pages 2551-2560.
Read now
Read now
Zlatko Fras & Dimitri P Mikhailidis. (2008) Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Current Medical Research and Opinion 24:9, pages 2467-2476.
Read now
Read now
CS Derdemezis, TD Filippatos, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opinion on Pharmacotherapy 9:11, pages 1829-1837.
Read now
Read now
E. S. Nakou, T. D. Filippatos, M. Georgoula, D. N. Kiortsis, A. D. Tselepis, D. P. Mikhailidis & M. S. Elisaf. (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Current Medical Research and Opinion 24:7, pages 1919-1929.
Read now
Read now
Steven Hildemann, Barbara Karmann, David Pittrow, Christian Barho, Harald Darius & Christoph Bode. (2008) Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care. Current Medical Research and Opinion 24:6, pages 1659-1668.
Read now
Read now
Carolyn R Harley, Sanjay K Gandhi, Herbert Heien, Ken McDonough & Stephanie P Nelson. (2008) Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opinion on Pharmacotherapy 9:5, pages 669-676.
Read now
Read now
A. H. Liem, A. P. van de Woestijne, A. H. Zwinderman, F. L. J. Visseren & J. W. Jukema. (2008) Determinants of CRP level in statin-treated patients. Current Medical Research and Opinion 24:4, pages 1065-1068.
Read now
Read now
M. Florentin, E. N. Liberopoulos, D. P. Mikhailidis & M. S. Elisaf. (2008) Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Current Medical Research and Opinion 24:4, pages 995-1009.
Read now
Read now
Henk W. O. Roeters van Lennep, An Ho Liem, Peter H. J. M. Dunselman, Geesje M. Dallinga-Thie, Aeilko H. Zwinderman & J. Wouter Jukema. (2008) The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Current Medical Research and Opinion 24:3, pages 685-694.
Read now
Read now
Dimitri P Mikhailidis & Martin Press. (2007) The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy 8:17, pages 3009-3020.
Read now
Read now
Irene F. Gazi, Stella S. Daskalopoulou, Devaki R. Nair & Dimitri P. Mikhailidis. (2007) Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Current Medical Research and Opinion 23:9, pages 2183-2192.
Read now
Read now
Articles from other publishers (70)
Michel Farnier, Raul D Santos, Juan Cosin-Sales, Marat V Ezhov, Jian Liu, Denis Granados, Serena Santoni, Irfan Khan & Alberico L Catapano. (2022) Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries. European Journal of Preventive Cardiology 29:17, pages 2264-2271.
Crossref
Crossref
Christie M. Ballantyne & Alberico L. Catapano. (2022) The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs. European Atherosclerosis Journal 1:1, pages 2-13.
Crossref
Crossref
Maria Cristina de Oliveira Izar, Viviane Zorzanelli Rocha Giraldez, Adriana Bertolami, Raul Dias dos SantosFilhoFilho, Ana Maria Lottenberg, Marcelo Heitor Vieira Assad, José Francisco Kerr Saraiva, Ana Paula M. Chacra, Tania L. R. Martinez, Luciana Ribeiro Bahia, Francisco Antonio Helfenstein Fonseca, Andre Arpad Faludi, Andrei C. Sposito, Antônio Carlos Palandri Chagas, Cinthia Elim Jannes, Cristiane Kovacs Amaral, Daniel Branco de Araújo, Dennys Esper Cintra, Elaine dos Reis Coutinho, Fernando Cesena, Hermes Toros Xavier, Isabela Cardoso Pimentel Mota, Isabela de Carlos Back Giuliano, José Rocha FariaNetoNeto, Juliana Tieko Kato, Marcelo Chiara Bertolami, Marcio Hiroshi Miname, Maria Helane Costa Gurgel Castelo, Maria Sílvia Ferrari Lavrador, Roberta Marcondes Machado, Patrícia Guedes de Souza, Renato Jorge Alves, Valeria Arruda Machado & Wilson SalgadoFilhoFilho. (2021) Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021. Arquivos Brasileiros de Cardiologia.
Crossref
Crossref
Changqing Sun, Wuyang Zheng, Ling Liang, Zuheng Liu, Wenchao Sun & Rong Tang. (2021) Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI. Journal of Interventional Cardiology 2021, pages 1-7.
Crossref
Crossref
Zlatko Fras & Dimitri P. Mikhailidis. (2021) Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). Current Vascular Pharmacology 19:5, pages 451-468.
Crossref
Crossref
N. V. Sych. (2021) ON THE POSSIBILITY OF USING CARBON ENTEROSORBENTS TO NORMALIZE CHOLESTEROL METABOLISM. Biotechnologia Acta 14:4, pages 64-69.
Crossref
Crossref
Angela Pirillo, Giuseppe D. Norata & Alberico L. Catapano. 2020.
Maria Lorenzi, Baishali Ambegaonkar, Carl A. Baxter, Jeroen Jansen, Michael J. Zoratti & Glenn Davies. (2018) Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clinical Research in Cardiology 108:5, pages 487-509.
Crossref
Crossref
Emmanuel Eroume-A. Egom, Rebabonye B. Pharithi, Soressa Hesse, Neasa Starr, Richard Armstrong, Habitha Mohammed Sulaiman, Katarina Gazdikova, Ioana Mozos, Martin Caprnda, Peter Kubatka, Peter Kruzliak, Barkat Khan, Ludovit Gaspar & Vincent M. G. Maher. (2019) Latest Updates on Lipid Management. High Blood Pressure & Cardiovascular Prevention.
Crossref
Crossref
Handrean Soran, Safwaan Adam & Paul N. Durrington. (2018) Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. Atherosclerosis 278, pages 135-142.
Crossref
Crossref
Nathan Wong, Stephen Nicholls, Joanne Tan & Christina Bursill. (2018) The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. International Journal of Molecular Sciences 19:6, pages 1680.
Crossref
Crossref
Amirhossein Sahebkar, Luis E. Simental-Mendía, Dimitri P. Mikhailidis, Matteo Pirro, Maciej Banach, Cesare R. Sirtori, Massimiliano Ruscica & Željko Reiner. (2018) Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Lipidology 12:3, pages 801-809.
Crossref
Crossref
Karel Kostev, Klaus G. Parhofer & Franz-Werner Dippel. (2017) Prevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemia. Cardiovascular Endocrinology 6:2, pages 81-85.
Crossref
Crossref
Amber B. Ouweneel, Ronald J. van der Sluis, Joya E. Nahon, Miranda Van Eck & Menno Hoekstra. (2017) Simvastatin treatment aggravates the glucocorticoid insufficiency associated with hypocholesterolemia in mice. Atherosclerosis 261, pages 99-104.
Crossref
Crossref
Kristine Scordo & Kim Anne Pickett. (2017) CE. AJN, American Journal of Nursing 117:1, pages 24-31.
Crossref
Crossref
Gisane Biacchi GomesAna Denise ZazulaLeonardo Seidi ShigueokaRosangela Alquieri FedatoAna Beatriz Brenner Affonso da CostaLuiz Cesar Guarita-SouzaCristina Pellegrino BaenaMarcia OlandoskiJosé Rocha Faria-Neto. (2017) A Randomized Open-Label Trial to Assess the Effect of Plant Sterols Associated with Ezetimibe in Low-Density Lipoprotein Levels in Patients with Coronary Artery Disease on Statin Therapy. Journal of Medicinal Food 20:1, pages 30-36.
Crossref
Crossref
A. Pirillo, G.D. Norata & A.L. Catapano. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
663
693
.
Barbara Nußbaumer, Anna Glechner, Angela Kaminski-Hartenthaler, Peter Mahlknecht & Gerald Gartlehner. (2016) Ezetimibe-Statin Combination Therapy: Efficacy and Safety as Compared With Statin Monotherapy. Deutsches Ärzteblatt international.
Crossref
Crossref
Theodosios D. Filippatos & Moses S. Elisaf. (2015) Statin–Ezetimibe Combination Therapy In Diabetic Individuals. Angiology 67:6, pages 507-509.
Crossref
Crossref
Swaytha Ganesh & Vinod K. Rustgi. (2016) Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 20:2, pages 351-364.
Crossref
Crossref
Lulu Li, Minli Zhang, Fuxiang Su, Yang Li, Yali Shen, Jie Shen & Daqing Zhang. (2015) Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes. Lipids in Health and Disease 14:1.
Crossref
Crossref
Vasilios G Athyros, Konstantinos Tziomalos, Niki Katsiki, Michael Doumas, Asterios Karagiannis & Dimitri P Mikhailidis. (2015) Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology 21:22, pages 6820-6834.
Crossref
Crossref
George N. Kouvelos, Eleni M. Arnaoutoglou, Haralampos J. Milionis, Vaia D. Raikou, Nektario Papa & Miltiadis I. Matsagkas. (2014) The Effect of Adding Ezetimibe to Rosuvastatin on Renal Function in Patients Undergoing Elective Vascular Surgery. Angiology 66:2, pages 128-135.
Crossref
Crossref
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis & Dimitri P. Mikhailidis. (2015) High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. Journal of Diabetes and its Complications 29:1, pages 142-145.
Crossref
Crossref
Niki Katsiki, Dimitri P. Mikhailidis & Devaki R. Nair. (2014) The effects of antiepileptic drugs on vascular risk factors: A narrative review. Seizure 23:9, pages 677-684.
Crossref
Crossref
Adriana Bertolami, Patrícia B. Botelho, Luciene F.L. Macedo, Dulcinéia S.P. Abdalla, André A. Faludi, Melissa Galasso & Inar A. Castro. (2014) Effect of plant sterols compared with ezetimibe on oxidative stress in patients treated with statins. Journal of Functional Foods 10, pages 178-186.
Crossref
Crossref
P. Deharo, M. Pankert, J. Quilici, C. Grosdidier, V. Verdier, G. Bonnet, P. Morange, M.-C. Alessi, J.-L. Bonnet & T. Cuisset. (2014) Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study. Annales de Cardiologie et d'Angéiologie 63:4, pages 222-227.
Crossref
Crossref
Konstantinos Tziomalos. (2014) Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World Journal of Hepatology 6:10, pages 738.
Crossref
Crossref
Jaspinder Kaur. (2014) A Comprehensive Review on Metabolic Syndrome. Cardiology Research and Practice 2014, pages 1-21.
Crossref
Crossref
Emilie GrenierGeneviève MailhotDanielle DionZaava RavidSchohraya SpahisMoise BendayanEmile Levy. (2013) Role of the apical and basolateral domains of the enterocyte in the regulation of cholesterol transport by a high glucose concentration. Biochemistry and Cell Biology 91:6, pages 476-486.
Crossref
Crossref
Thomas F. WhayneJrJr. (2012) Assessment of Low-Density Lipoprotein Targets. Angiology 64:6, pages 411-416.
Crossref
Crossref
Venkata M. Alla, Vrinda Agrawal, Andrew DeNazareth, Syed Mohiuddin, Sudha Ravilla & Marc Rendell. (2013) A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs. Drugs 73:10, pages 1025-1054.
Crossref
Crossref
M.K.H. Shah, W.R. Critchley, N. Yonan, S.G. Williams & S.M. Shaw. (2013) Second Line Options for Hyperlipidemia Management after Cardiac Transplantation. Cardiovascular Therapeutics 31:3, pages 138-146.
Crossref
Crossref
J. G. Jimenez, J. B. Rosen, V. Pirags, R. Massaad, M. E. Hanson, P. Brudi & J. Triscari. (2013) The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. Diabetes, Obesity and Metabolism 15:6, pages 513-522.
Crossref
Crossref
Ming-Hui ChenJoseph G. IbrahimArvind K. ShahJianxin LinHui Yao. (2012) Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs. Statistics in Medicine 31:28, pages 3597-3616.
Crossref
Crossref
Michael S. Kostapanos, Moses S. Elisaf & Dimitri P. Mikhailidis. (2012) Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 17:4, pages 427-427.
Crossref
Crossref
Michael S Kostapanos, Dimitri P Mikhailidis & Moses S Elisaf. (2012) Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. Future Cardiology 8:6, pages 813-817.
Crossref
Crossref
Michael S. Kostapanos, Moses S. Elisaf & Dimitri P. Mikhailidis. (2012) Ezetimibe – a new approach in hypercholesterolemia management. Pharmacological Reports 64:4, pages 997-998.
Crossref
Crossref
Peter P. Toth, Christie M. Ballantyne, Michael H. Davidson, Joanne E. Tomassini, Dena Rosen Ramey, David Neff, Andrew M. Tershakovec, X. Henry Hu & Kaan Tunceli. (2012) Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. Journal of Clinical Lipidology 6:2, pages 180-191.
Crossref
Crossref
Silvia Di Legge, Giacomo Koch, Marina Diomedi, Paolo Stanzione & Fabrizio Sallustio. (2012) Stroke Prevention: Managing Modifiable Risk Factors. Stroke Research and Treatment 2012, pages 1-15.
Crossref
Crossref
Harold E. Bays, Scott E. Conard, Lawrence A. Leiter, Steven R. Bird, Robert S. Lowe & Andrew M. Tershakovec. (2011) Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. International Journal of Cardiology 153:2, pages 141-147.
Crossref
Crossref
Niki Katsiki, Eirini Lioudaki, Emmanuel S. Ganotakis & Dimitri P. Mikhailidis. (2011) Impact of Ezetimibe Coadministered With Statins on Cardiovascular Events Following Acute Coronary Syndrome: A 3-Year Population-Based Retrospective Cohort Study in Taiwan. Clinical Therapeutics 33:12, pages 2091.
Crossref
Crossref
Kosmas I. ParaskevasAlkistis Pantopoulou, Ioannis S. Vlachos, George Agrogiannis, Dimitrios G. Iliopoulos, Gabriel Karatzas, Dimitrios Tzivras, Dimitri P. Mikhailidis & Despina N. Perrea. (2011) Comparison of Fibrate, Ezetimibe, Low- and High-Dose Statin Therapy for the Dyslipidemia of the Metabolic Syndrome in a Mouse Model. Angiology 62:2, pages 144-154.
Crossref
Crossref
Howard S. Friedman, Srinivasan Rajagopalan, Jaime P. Barnes & Hal Roseman. (2011) Combination Therapy With Ezetimibe/Simvastatin Versus Statin Monotherapy for Low-Density Lipoprotein Cholesterol Reduction and Goal Attainment in a Real-World Clinical Setting. Clinical Therapeutics 33:2, pages 212-224.
Crossref
Crossref
John S. Sampalis, Stéphane Bissonnette & Stella Boukas. (2011) Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model. Advances in Preventive Medicine 2011, pages 1-7.
Crossref
Crossref
Michael Derks, Markus Abt & Mary Phelan. (2010) Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe. British Journal of Clinical Pharmacology 70:6, pages 825-833.
Crossref
Crossref
M. H. Ahmed & C. D. Byrne. (2010) Potential therapeutic uses for ezetimibe beyond lowering LDL‐c to decrease cardiovascular events. Diabetes, Obesity and Metabolism 12:11, pages 958-966.
Crossref
Crossref
T. McCormack, P. Harvey, R. Gaunt, V. Allgar, R. Chipperfield & P. Robinson. (2010) Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. International Journal of Clinical Practice 64:8, pages 1052-1061.
Crossref
Crossref
Maurizio Averna, Augusto Zaninelli, Cristina Le Grazie & Gian Franco Gensini. (2010) Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. Journal of Clinical Lipidology 4:4, pages 272-278.
Crossref
Crossref
Andres Jaussi, Georg Noll, Bernhard Meier & Roger Darioli. (2010) Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland. European Journal of Cardiovascular Prevention & Rehabilitation 17:3, pages 363-372.
Crossref
Crossref
Laurent Drogoul, Didier Scarlatti & Émile Ferrari. (2010) Syndrome coronaire aigu sans sus-décalage de ST : traitement et prise en charge au décours. La Presse Médicale 39:3, pages 332-337.
Crossref
Crossref
Jeffrey Cohn, Alvin Kamili, Elaine Wat, Rosanna W. Chung & Sally Tandy. (2010) Dietary Phospholipids and Intestinal Cholesterol Absorption. Nutrients 2:2, pages 116-127.
Crossref
Crossref
Geneviève Dubuc, Michel Tremblay, Guillaume Paré, Hélène Jacques, Josée Hamelin, Suzanne Benjannet, Lucie Boulet, Jacques Genest, Lise Bernier, Nabil G. Seidah & Jean Davignon. (2010) A new method for measurement of total plasma PCSK9: clinical applications. Journal of Lipid Research 51:1, pages 140-149.
Crossref
Crossref
Almasa Bass, Alan L Hinderliter & Craig R Lee. (2009) The Impact of Ezetimibe on Endothelial Function and Other Markers of Cardiovascular Risk. Annals of Pharmacotherapy 43:12, pages 2021-2030.
Crossref
Crossref
Jörg Slany. (2009) Zielwerterreichung unter lipidsenkender Therapie mit Ezetimib/Simvastatin bei Patienten mit Atherosklerose und/oder Diabetes mellitus – eine österreichische AnwendungsbeobachtungAchievement of blood lipid target levels with Ezetimibe/Simvastatin in patients with atherosclerosis and/or diabetes mellitus – an Austrian observational study. Wiener Medizinische Wochenschrift 159:21-22, pages 558-564.
Crossref
Crossref
Manfredi Rizzo, Giovam Battista Rini, Giatgen A. Spinas & Kaspar Berneis. (2009) The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?. Atherosclerosis 204:2, pages 330-333.
Crossref
Crossref
V. Atella, A. Brady, A.L. Catapano, J. Critchley, I.M. Graham, F.D.R. Hobbs, J. Leal, P. Lindgren, D. Vanuzzo, M. Volpe, D. Wood & R. Paoletti. (2009) Bridging science and health policy in cardiovascular disease: focus on lipid management. Atherosclerosis Supplements 10:1, pages 3-21.
Crossref
Crossref
Michael James Zema. (2009) Add-on therapy for hypercholesterolemia: a pilot comparison of two gastrointestinally-acting agents in statin-treated patients. Journal of Clinical Lipidology 3:2, pages 119-124.
Crossref
Crossref
Paul Hamilton. (2009) Role of ezetimibe in the management of patients with atherosclerosis. Coronary Artery Disease 20:2, pages 169-174.
Crossref
Crossref
Georgios S. Goumas. (2008) Is There Evidence-based Hypolipidemic Treatment with Clinical Benefit beyond Statins?. Angiology 60:1, pages 93-98.
Crossref
Crossref
Marc-Andre Cornier, Dana Dabelea, Teri L. Hernandez, Rachel C. Lindstrom, Amy J. Steig, Nicole R. Stob, Rachael E. Van Pelt, Hong Wang & Robert H. Eckel. (2008) The Metabolic Syndrome. Endocrine Reviews 29:7, pages 777-822.
Crossref
Crossref
Thomas F. WhayneJrJr. (2008) Is There a Problem With Ezetimibe or Just ENHANCEd Hype?. Angiology 59:6, pages 661-663.
Crossref
Crossref
John Strony, Robert Hoffman, Mary Hanson & Enrico Veltri. (2008) Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: Results from two open-label extension studies in hypercholesterolemic patients. Clinical Therapeutics 30:12, pages 2280-2297.
Crossref
Crossref
Scott E. Conard, Harold E. Bays, Lawrence A. Leiter, Steven R. Bird, Joseph Rubino, Robert S. Lowe, Joanne E. Tomassini & Andrew M. Tershakovec. (2008) Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.. The American Journal of Cardiology 102:11, pages 1489-1494.
Crossref
Crossref
K. von Bergmann. (2008) Disodium ascorbyl phytostanol phosphate. A new cholesterol-lowering drug?. European Journal of Clinical Pharmacology 64:7, pages 649-650.
Crossref
Crossref
Osamah Hussein, LiLia Minasian, Yaroslav Itzkovich, Karina Shestatski, Lizora Solomon & Jamal Zidan. (2008) Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. British Journal of Clinical Pharmacology 65:5, pages 637-645.
Crossref
Crossref
Dawn M. Torres & Stephen A. Harrison. (2008) Diagnosis and Therapy of Nonalcoholic Steatohepatitis. Gastroenterology 134:6, pages 1682-1698.
Crossref
Crossref
A. Viljoen & A. S. Wierzbicki. (2008) Enhanced LDL-C reduction: lower is better. Does it matter how?. International Journal of Clinical Practice 62:4, pages 518-520.
Crossref
Crossref
Adam P. Levine, Dimitri P. MikhailidisTessa Moross, Karen Benson & Mayur Gor. (2008) Achieving Vascular Risk Factor Targets: A Survey of a London General Practice. Angiology 59:1, pages 36-46.
Crossref
Crossref
V. Charlton-Menys & P. N. Durrington. (2008) Human cholesterol metabolism and therapeutic molecules. Experimental Physiology 93:1, pages 27-42.
Crossref
Crossref